Skip to main content
Premium Trial:

Request an Annual Quote

Horizon to Use Genome Editing Technology to Support Bayer Pharma Cancer R&D Programs

NEW YORK (GenomeWeb News) – Horizon Discovery today announced it has signed an agreement with Bayer Pharma for the use of Horizon's Genesis genome editing technology in support of Bayer's cancer R&D programs.

Horizon will use its platform to develop human isogenic cell lines for use in Bayer's programs in order to deliver cell lines that more accurately model the disease-relevant mutations found in human tumors.

Genesis allows for the alteration of endogenous gene sequence of human and mammalian cell lines without unwanted or confounding genotypes and/or phenotypes and can more accurately reflect patient genotypes in human cancer cell lines derived from human tumors, Horizon said.

Financial and other terms of the deal were not disclosed.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.